Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time

Philip M. Arlen, Fernando Bianco, William L. Dahut, Anthony D'Amico, William D. Figg*, Stephen J. Freedland, James L. Gulley, Philip W. Kantoff, Michael W. Kattan, Andrew Lee, Meredith M. Regan, Oliver Sartor

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

112 Scopus citations

Abstract

Purpose: Prostate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. Prostate specific antigen doubling time, or the change in prostate specific antigen over time, has emerged as a useful predictive marker for assessing disease outcome in patients with prostate cancer. It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting. Materials and Methods: In September 2006 a conference was held at the National Cancer Institute in Bethesda, Maryland to define these parameters and develop guidelines for their use. Results: The Prostate Specific Antigen Working Group defined criteria regarding prostate specific antigen doubling time including the calculation of prostate specific antigen doubling time, evidence to support prostate specific antigen doubling time as a predictive factor in the setting of biochemical recurrence and the use of prostate specific antigen doubling time as a stratification factor in clinical trials. Conclusions: We propose that investigators calculate prostate specific antigen doubling time before enrolling patients in clinical studies and calculate it as an additional measurement of therapeutic activity. We believe we have developed practical guidelines for the calculation of prostate specific antigen doubling time and its use as a measurement of prognosis and outcome. Furthermore, the use of common standards for prostate specific antigen doubling time in clinical trials is important as we determine which treatments should progress to randomized trials in which "hard" end points such as survival will be used.

Original languageEnglish
Pages (from-to)2181-2186
Number of pages6
JournalJournal of Urology
Volume179
Issue number6
DOIs
StatePublished - Jun 2008
Externally publishedYes

Keywords

  • biological markers
  • clinical trials as topic
  • consensus
  • prostate-specific antigen
  • prostatic neoplasms

Fingerprint

Dive into the research topics of 'Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time'. Together they form a unique fingerprint.

Cite this